Retatrutide: Complete Guide to the Triple-Agonist Research

Each receptor adds a different lever. GLP-1 receptor agonism stimulates nutrient-induced insulin release, lowers glucagon secretion and acts on central and peripheral pathways that regulate energy balance. GIP is the other incretin hormone, and the discovery work attributed the drop in calorie intake to the GIP- and GLP-1-receptor arms of the molecule.^[11][1]

The glucagon receptor is the new element. Glucagon is best known for raising blood glucose, but reviews of the field describe further roles: stimulating lipolysis and fat oxidation in the liver, reducing calorie intake and increasing energy expenditure, the last shown at least in animal models. In obese mice, adding glucagon-receptor activity to the incretin arms augmented weight loss through higher energy expenditure.^[12][1]

Two cautions follow. The energy-expenditure mechanism is established in animals; how chronic glucagon-receptor activation behaves in humans, including its risks, is still being worked out, and the review literature says so directly. And because glucagon raises glucose, glucagon-based compounds are paired with GLP-1 activity to offset that effect. The balance between the arms is a design choice, not a given.^[12]

The pivotal phase 2 trial, published in the New England Journal of Medicine in 2023, randomised 338 adults with obesity, or overweight plus a weight-related condition, to weekly retatrutide at 1, 4, 8 or 12 mg or to placebo for 48 weeks. Participants did not have diabetes. The primary endpoint was the percentage change in body weight at 24 weeks.^[3]

At 24 weeks, the least-squares mean change in body weight was −7.2% in the 1 mg group, −12.9% at 4 mg, −17.3% at 8 mg and −17.5% at 12 mg, against −1.6% with placebo. At 48 weeks the figures were −8.7%, −17.1%, −22.8% and −24.2%, against −2.1%. In the 12 mg group, 83% of participants had reached a reduction of at least 15% by week 48, compared with 2% on placebo.^[3]

Two details shape how those numbers should be read. Gastrointestinal adverse events were dose-related and were partially mitigated by a lower starting dose in the escalation arms, and heart rate rose in a dose-dependent way, peaking at 24 weeks before declining. It was also a phase 2 trial: modest group sizes, 48 weeks of follow-up and no hard clinical outcomes such as cardiovascular events.^[3]

A separate phase 2 trial randomised 281 people with type 2 diabetes in the USA to retatrutide, placebo or dulaglutide, an established GLP-1 receptor agonist. At 24 weeks, HbA1c fell by up to 2.02 percentage points in the 12 mg escalation group, against 0.01 with placebo and 1.41 with dulaglutide. At 36 weeks, body weight had fallen by up to 16.94%. No severe hypoglycaemia and no deaths were reported.^[4]

A substudy of the obesity trial followed 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat. At 24 weeks, liver fat fell by a mean of 42.9% relative to baseline at 1 mg and by 81.4% and 82.4% at 8 and 12 mg, against a 0.3% rise with placebo; 86% of the 12 mg group reached normal liver fat, below 5%. Liver-fat content is a surrogate measure, not evidence on fibrosis or long-term liver outcomes.^[5]

A body-composition substudy of the diabetes trial measured fat mass by DXA scan at 36 weeks. Total fat mass fell by 26.1% in the pooled 8 mg groups and by 23.2% at 12 mg, against 4.5% with placebo, and the authors reported that the share of weight lost as lean mass was similar to other obesity treatments. Only 103 participants completed both scans, which limits precision.^[6]

The first peer-reviewed phase 3 result is TRANSCEND-T2D-1, published in The Lancet in 2026. It randomised 537 adults with type 2 diabetes managed by diet and exercise alone, at sites in the USA, Mexico and India, to weekly retatrutide at 4, 9 or 12 mg or to placebo for 40 weeks. HbA1c fell by 1.69, 1.86 and 1.94 percentage points, against 0.81 with placebo, and body weight fell by 11.5%, 13.9% and 15.3%, against 2.6%.^[7]

In that trial, discontinuations due to adverse events were 2–5% with retatrutide and 0% with placebo. The most frequent events were mild-to-moderate gastrointestinal effects that subsided over time, and no severe hypoglycaemia was reported. Two deaths occurred in the 4 mg group; both were judged unrelated to the study drug.^[7]

The obesity programme, TRIUMPH, comprises four phase 3 trials in more than 5,800 participants: basket trials that nest obstructive sleep apnoea and knee osteoarthritis studies inside weight-management trials, a trial in people with cardiovascular disease, and a stand-alone osteoarthritis trial. TRIUMPH-1 is listed as completed on ClinicalTrials.gov, and a kidney trial, TRANSCEND-CKD, has published its design. This guide adds phase 3 obesity results once they appear in a peer-reviewed journal.^[8][9][10]

Across the published trials, the dominant adverse events were gastrointestinal (nausea, diarrhoea, vomiting and constipation), mostly mild to moderate and dose-related. In the diabetes phase 2 trial they were reported by 35% of participants on retatrutide, ranging from 13% at the lowest dose to 50% in one fast-escalation group, against 13% on placebo. In the obesity trial, heart rate rose in a dose-dependent way before declining after week 24.^[4][3]

Dysaesthesia, meaning abnormal skin sensations such as burning or tingling, has been observed in clinical trials of retatrutide as well as semaglutide and tirzepatide. A 2026 pharmacovigilance analysis strengthened the evidence for this class-wide signal and found it more frequent at higher doses and with more potent GLP-1 receptor agonists.^[13]

What is unknown matters as much. The published phase 2 and 3 trials ran for 36 to 48 weeks and none was designed to measure cardiovascular events or long-term safety, and a 2026 BMJ network meta-analysis rated the certainty of evidence for emerging agents, retatrutide included, as very low to low. A 2026 case report described a person with type 1 diabetes who became acutely unwell after using an online-purchased product sold as retatrutide; causation could not be established, and the authors noted that the composition and purity of such products may be uncertain.^{[3][4][7][14][15]}

No. Retatrutide is an investigational compound. The 2026 phase 3 publication describes it as under clinical development for type 2 diabetes, obesity and related complications, and the European Medicines Agency's database of authorised medicines lists no retatrutide product and no EPAR as of September 2026.^[7][17]

Anti-doping science has started to catch up. A 2026 study developed and validated a mass-spectrometry method for retatrutide in human plasma and urine according to WADA criteria, citing concern about misuse in sport. In samples from four people who had self-administered the compound, no retatrutide was detected in urine, while plasma remained a usable matrix for approximately 56 days after the first dose.^[16]

Status can change once phase 3 data are submitted to regulators. The EMA medicines database is where an EU authorisation would appear, and this guide will be updated if one does.^[17]

Peptyds supplies retatrutide as a lyophilised research peptide for in-vitro laboratory work, with the batch documentation described on our quality page. It is not a medicine, it is not supplied for human or veterinary use, and nothing on this page describes how a person should use it.

The evidence record is worth knowing precisely: a triple GIP, GLP-1 and glucagon receptor agonist with published phase 1 and 2 data, a first peer-reviewed phase 3 trial in type 2 diabetes, obesity trials registered as completed but without peer-reviewed results at the time of writing, and no EU marketing authorisation. Research interest in the molecule is legitimate. Consumer weight-loss claims are not supported by that record.^{[1][3][7][9][17]}